Mesenchymal stem cells expressing therapeutic genes induce autochthonous prostate tumour regression.

[1]  V. Altanerová,et al.  Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario , 2014, International journal of cancer.

[2]  A. Caplan,et al.  MSCs: Delivery Routes and Engraftment, Cell-Targeting Strategies, and Immune Modulation , 2013, Stem cells international.

[3]  P. Lehenkari,et al.  Cell Surface Structures Influence Lung Clearance Rate of Systemically Infused Mesenchymal Stromal Cells , 2013, Stem cells.

[4]  K. Shah.  Encapsulated stem cells for cancer therapy , 2013, Biomatter.

[5]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[6]  J. Marshall,et al.  Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials , 2012, PloS one.

[7]  K. Shah.  Mesenchymal stem cells engineered for cancer therapy. , 2012, Advanced drug delivery reviews.

[8]  M. Babič,et al.  Human adipose tissue‐derived mesenchymal stem cells expressing yeast cytosinedeaminase::uracil phosphoribosyltransferase inhibit intracerebral rat glioblastoma , 2012, International journal of cancer.

[9]  R. Malekzadeh,et al.  In vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis. , 2011, Nuclear medicine and biology.

[10]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European Urology.

[11]  S. Kang,et al.  Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. , 2011, Stem cells and development.

[12]  T. Ritter,et al.  Immunological aspects of allogeneic mesenchymal stem cell therapies. , 2010, Human gene therapy.

[13]  E. Seifried,et al.  Suspension medium influences interaction of mesenchymal stromal cells with endothelium and pulmonary toxicity after transplantation in mice. , 2010, Cytotherapy.

[14]  M. Andreeff,et al.  Direct Evidence of Mesenchymal Stem Cell Tropism for Tumor and Wounding Microenvironments Using In Vivo Bioluminescent Imaging , 2009, Stem cells.

[15]  P. Delafontaine,et al.  Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. , 2009, Cell stem cell.

[16]  Sanjiv S. Gambhir,et al.  Trafficking Mesenchymal Stem Cell Engraftment and Differentiation in Tumor‐Bearing Mice by Bioluminescence Imaging , 2009, Stem cells.

[17]  S. Savitz,et al.  Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. , 2009, Stem cells and development.

[18]  N. Dawson,et al.  Emerging therapies in castrate-resistant prostate cancer , 2009, Current opinion in oncology.

[19]  M. Matúšková,et al.  Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice , 2008, The journal of gene medicine.

[20]  M. Danks,et al.  Stem and progenitor cell-mediated tumor selective gene therapy , 2008, Gene Therapy.

[21]  W. Hahn,et al.  The current state of preclinical prostate cancer animal models , 2008, The Prostate.

[22]  B. Giusti,et al.  Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model , 2008, Archives of Dermatological Research.

[23]  M. Matúšková,et al.  Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. , 2007, Cancer research.

[24]  R. Robbins,et al.  Stem cell transplantation: the lung barrier. , 2007, Transplantation proceedings.

[25]  K. Ow,et al.  Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice , 2006, The journal of gene medicine.

[26]  Dong Soo Lee,et al.  Tissue distribution of 18F-FDG-labeled peripheral hematopoietic stem cells after intracoronary administration in patients with myocardial infarction. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  V. Eder,et al.  Influence of hypoxia on the domiciliation of Mesenchymal Stem Cells after infusion into rats: possibilities of targeting pulmonary artery remodeling via cells therapies? , 2005, Respiratory research.

[28]  G. Tozer,et al.  From bench to bedside for gene-directed enzyme prodrug therapy of cancer. , 2005, Anti-cancer drugs.

[29]  N. Greenberg,et al.  Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization , 2005, European journal of immunology.

[30]  Ernst J. Rummeny,et al.  Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  J. Haseman,et al.  A Grading Scheme for the Assessment of Proliferative Lesions of the Mouse Prostate in the TRAMP Model , 2003, Toxicologic pathology.

[32]  B. Foster,et al.  The TRAMP Mouse as a Model for Prostate Cancer , 2001, Current protocols in immunology.

[33]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[34]  A. Caplan,et al.  The Dynamic in vivo Distribution of Bone Marrow-Derived Mesenchymal Stem Cells after Infusion , 2001, Cells Tissues Organs.

[35]  P. Leroy,et al.  In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. , 2000, Cancer research.

[36]  M. Kattan,et al.  Androgen-independent prostate cancer progression in the TRAMP model. , 1997, Cancer research.

[37]  B. Foster,et al.  Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. , 1997, Cancer research.

[38]  R. Matusik,et al.  Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[39]  T. Dittmar,et al.  Migratory properties of mesenchymal stem cells. , 2013, Advances in biochemical engineering/biotechnology.

[40]  V. Altanerová,et al.  Stem cell based glioblastoma gene therapy. , 2012, Neoplasma.

[41]  M. Matúšková,et al.  Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[42]  P. Kasten,et al.  Survival of human mesenchymal stromal cells from bone marrow and adipose tissue after xenogenic transplantation in immunocompetent mice. , 2008, Cytotherapy.

[43]  E. Coligan.  Current protocols in immunology , 1991 .